Earnings Call Summary | PolyPid(PYPD.US) Q1 2024 Earnings Conference
Earnings Call Summary | PolyPid(PYPD.US) Q1 2024 Earnings Conference
The following is a summary of the PolyPid Ltd (PYPD) Q1 2024 Earnings Call Transcript:
以下是Polypid Ltd（PYPD）2024年第一季度财报电话会议记录的摘要：
Financial Performance:
财务业绩：
PolyPid reported Q1 2024 cash and short-term deposits of $14.5 million.
Research and development expenses for this period were $5.1 million, up from $3.8 million in Q1 2023, mainly due to the SHIELD II Phase III trial.
The company saw a net loss of $6.4 million for this quarter, a slight increase compared to the $6.1 million net loss in Q1 2023.
Polypid报告称，2024年第一季度现金和短期存款为1,450万美元。
该期间的研发费用为510万美元，高于2023年第一季度的380万美元，这主要归因于SHIELD III三期试验。
该公司本季度净亏损640万美元，与2023年第一季度的610万美元净亏损相比略有增加。
Business Progress:
业务进展：
PolyPid has enrolled over 200 subjects in its SHIELD II trial for D-PLEX100, with the Data Safety Monitoring Committee recommending continuation of the study without modifications.
The company has secured considerable intellectual property protection for D-PLEX100 with about 175 granted and pending patent applications.
It gathered around $15 million from private placement financing in January 2024, with potential to secure an additional $19 million if the interim analysis results are positive and all warrants are exercised.
Polypid 已招募了 200 多名受试者参加 D-PLEX100 的 SHIELD II 试验，数据安全监测委员会建议在不进行修改的情况下继续进行这项研究。
该公司已经为 D-PLEX100 获得了相当大的知识产权保护，共有大约 175 项已获批准和待处理的专利申请。
它在2024年1月从私募融资中筹集了约1500万美元，如果中期分析结果为正面且所有认股权证都得到行使，则有可能再获得1900万澳元。
More details: PolyPid IR
更多详情： Polypid IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。